Risk of Cardiac Disease in a Population-Based Cohort of Myotonic Dystrophy Type 1 and Type 2 in the United States
This study confirms the increased risk of cardiac arrhythmias in individuals with DM and DM2 and identifies the development of cardiomyopathy as a low-frequency event. Notably, the risk of cardiac arrhythmias is particularly elevated in DM1. The study reaffirms the need for serial cardiac monitoring in individuals with DM1/DM2.
Authors
- Nicholas E. Johnson (ORCID: https://orcid.org/0000-0002-3917-4257)
- Aida Soim (ORCID: https://orcid.org/0000-0001-7687-751X)
- Treeva Jaff (ORCID: https://orcid.org/0000-0002-6418-4588)
- Frank J. Raucci (ORCID: https://orcid.org/0000-0002-3464-6569)
- Emma Ciafaloni (ORCID: https://orcid.org/0000-0002-3925-3289)
- Vinay Bhandaru
- Yedatore Venkatesh (ORCID: https://orcid.org/0009-0007-7311-4905)
- Madeline Murguia Rice (ORCID: https://orcid.org/0000-0001-5299-9723)
- Jennifer Andrews (ORCID: https://orcid.org/0000-0002-0064-3933)
Institutions
- New York State Department of Health (US)
- University of Arizona (US)
- University of South Carolina (US)
- Virginia Commonwealth University (US)
- George Washington University (US)
- Children's Hospital of Richmond at VCU (US)
- University of Rochester (US)
Publication Details
- Journal
- Neurology Genetics
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1212/nxg.0000000000200322
- Citations
- 1
- Primary Topic
- Genetic Neurodegenerative Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.91
Funders
- Sanofi
- Vertex Pharmaceuticals
- Sarepta Therapeutics
- Centers for Disease Control and Prevention
- Sanofi Genzyme
- National Heart, Lung, and Blood Institute
- National Center for Advancing Translational Sciences